For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Shares of Pfizer Inc. PFE slid 2.18% to $23.29 Thursday, on what proved to be an all-around dismal trading session for the ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...

President Trump urges top pharmaceutical firms to lower U.S. drug prices under his most-favored-nation drug pricing policy ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

It is worth considering Pfizer (PFE), which belongs to the Zacks Large Cap Pharmaceuticals industry. This drugmaker has an established record of topping earnings estimates, especially when looking at ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...